Meanwhile, CAPItello-292 aims to evaluate the efficacy and safety of the added benefit of capivasertib (AKT inhibitor) combined with CDK4/6i and fulvestrant in participants with locally advanced (inoperable) or metastatic HR+/HER2− breast cancer patients who have relapsed during adjuvant endocrine therapy. This evidence concerns the gene AKT1 and breast carcinoma.